

# Edvan De Queiroz Crusoe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6510717/publications.pdf>

Version: 2024-02-01

49  
papers

1,035  
citations

758635

12  
h-index

454577

30  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1277  
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	13.9	268
2	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2361-2371.	6.3	177
3	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.	1.7	144
4	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
5	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.	1.1	61
6	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
7	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
8	Observational study of multiple myeloma in Latin America. <i>Annals of Hematology</i> , 2017, 96, 65-72.	0.8	29
9	New proteasome inhibitors in the treatment of multiple myeloma. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 76-83.	0.1	25
10	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
11	Multiple myeloma and central nervous system involvement: experience of a Brazilian center. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 30-36.	0.1	15
12	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476.	0.6	13
13	Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e43-e50.	0.2	13
14	Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013, 35, 201-17.	0.7	12
15	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	2.0	12
16	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.2	11
17	Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committee. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 200-205.	0.1	10
18	Outcomes of autologous transplantation for multiple myeloma according to different induction regimens. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 19-24.	0.7	9

#	ARTICLE	IF	CITATIONS
19	Multiple Myeloma: A Rare Case in an 8-Year-Old Child. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e31-e33.	0.2	9
20	Bilateral breast plasmacytoma: a clinical case report. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 166-169.	0.7	9
21	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	0.8	9
22	Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 257-269.	0.8	7
23	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	0.8	7
24	For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 331-336.	0.7	4
25	Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 302-309.	0.7	3
26	Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 118-124.	0.1	2
27	Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 417-423.	0.1	2
28	The impact of lactate dehydrogenase (LDH) in association with the International Staging System (ISS) on patients with multiple myeloma.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e93.	0.2	1
29	A Phase III Study Comparing Thalidomide/Cyclophosphamide/ Dexamethasone Vs Thalidomide/Dexamethasone Vs Thalidomide/Melphalan/Prednisone In De Novo Multiple Myeloma Patients Not Eligible for ASCT. <i>Blood</i> , 2011, 118, 5117-5117.	0.6	1
30	Comparison of Kappa & Lambda FreeLite to Total Kappa & Lambda Immunoassays for the Detection of Monoclonal Gammopathies, Both As Standalone Tests and Alongside Serum Protein Electrophoresis. <i>Blood</i> , 2014, 124, 5705-5705.	0.6	1
31	Hepatosplenic T-cell lymphoma associated to thiopurine in Ulcerative Colitis patient from Brazil: A case report. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S52.	0.9	0
32	Primary Plasma Cell Leukemia: Epidemiologic and Clinical Profile from Patients Treated in a Brazilian Single Hematology and BMT Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S338-S339.	0.2	0
33	Identification of Amyloid Component in Bone Marrow Biopsy of Patients in the Diagnosis of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S339-S340.	0.2	0
34	Analysis of the Availability of Anti-Myeloma Drugs and Impact on the Current Management of Myeloma in Latin American Countries. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e15-e16.	0.2	0
35	Outcomes of Fresh Peripheral Stem Cell Transplants (PSCT) compared to Cryopreserved PSCT for the Treatment of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S309-S310.	0.2	0
36	Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e145-e146.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Results of the Daratumumab Monotherapy Early Access Treatment Protocol (EAP) in Patients from Brazil With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e246-e247.	0.2	0
38	Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.. <i>Blood</i> , 2009, 114, 3834-3834.	0.6	0
39	Evaluation of Angiogenesis and the CD57+ Lymphocytic Population on Bone Marrow Biopsies (BM) in Multiple Myeloma Patients Treated with Thalidomide (Thal). <i>Blood</i> , 2011, 118, 5095-5095.	0.6	0
40	Venous Thromboembolism Prophylaxis with Aspirin for Multiple Myeloma Patients Receiving Thalidomide Combination As First-Line Treatment. <i>Blood</i> , 2014, 124, 5764-5764.	0.6	0
41	Prevalence of Oligoclonal Bands in Multiple Myeloma Patients Who Achieved Better Results Than Very Good Partial Response after Treatment with Standard or High Doses Chemotherapy-Final Analysis. <i>Blood</i> , 2015, 126, 4210-4210.	0.6	0
42	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016, 128, 3276-3276.	0.6	0
43	Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma. <i>Blood</i> , 2021, 138, 4927-4927.	0.6	0
44	COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM). <i>Blood</i> , 2021, 138, 4104-4104.	0.6	0
45	Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients. <i>Blood</i> , 2021, 138, 3943-3943.	0.6	0
46	First Description of Upfront Target Therapy Treating AML and Bcll Presented Simultaneously As First Line. <i>Blood</i> , 2020, 136, 25-26.	0.6	0
47	Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
48	Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
49	Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project. <i>Blood</i> , 2020, 136, 4-4.	0.6	0